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The main reason for development of CF for the Chuvash − the ﬁfth in popu-
lation number (1.5 mln) nationality in Russia is of the “mild” p.E92K mutation
(p.Glu92Lys, c.274G>A).
Objective: To identify the clinical and functional characteristics of the course of
CF in the patients-carriers of p.E92K mutation.
Materials and Methods: Group 1: 26 adult CF patients homozygous or heterozy-
gous for E92K, group 2: 103 adult patients homozygous for F508del. Age, age di-
agnosis, BMI, level of chloride in sweat, spirometry parameters, frequency of some
complications [CF related diabetes (CFRD), liver cirrhosis with portal hyperten-
sion (LCPH), distal intestinal obstruction syndrome (DIOS)/meconium ileus (MI)
in past medical history, cholelithiasis, urolithiasis, pulmonary hypertension (PH),
asthma] were estimated. Results are described as mean±SD/median (IQR).
Results: The median age group 1 was: 26.0 (5.95) years, higher than in the
group 2 − 23.6 (6.5) years (p = 0.007); age diagnosis of patients with E92K
was: 13.3 (9.2), higher than among homozygous for F508del − 1.9 (4.5) years
(p< 0.001). There was no signiﬁcant difference in the level of chloride in sweat
(101±30.5mmol/l vs 103±32mmol/l respectively) in the two groups. The spirome-
try parameters, BMI, the frequency of LCPH, DIOS/MI, cholelithiasis, urolithiasis,
asthma and PH had not signiﬁcant difference. CFRD had frequency in the group
of the patients homozygous for F508del, and CFRD in group p.E92K was never
once identiﬁed (p = 0.046).
Conclusion: p.E92K mutation in patients-carriers is associated with late onset age,
signiﬁcant low frequency of CERD, what is likely connected with the “mildness”
of this mutation.
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Background: Cystic ﬁbrosis (CF) is one of the most common severe autosomal
recessive diseases in Latvia with frequency 1:3,300. It is classiﬁed as I class
mutation causing a premature stop codon formation in exon 4. The phenotype
is associated with early onset of disease and exocrine pancreatic insufﬁciency. So
far only few cases with homozygous dele2,3 mutations have been described.
Methods: CFTR mutation screening was performed by standard molecular methods
for 62 patients with clinical symptoms of CF.
Results: CFTR dele2,3 mutation was detected in 3 patients. The ﬁrst was a girl
with dF508/dele2,3 mutation who was diagnosed with CF at the age of 1 year due
to poor weight gain, recurrent lung infections and positive sweat test. On therapy
there was a symptom free period of several years. She died at the age of 13 years
due to pulmonary and heart insufﬁciency. The second was a boy with P67L/dele2,3
mutation presented with meconium ileus and had died at the age of 3 months.
The third patient, a girl, presented with meconium ileus and positive sweat test
in ﬁrst days of her life. The molecular testing revealed her to be homozygous for
dele2,3 mutation. At the age of 1 year and 6 months, even having pancreatic enzyme
replacement therapy, her height and weight is still below 3rd percentile.
Conclusion: CFTR dele2,3 (21 kb) mutation represents 3.2% of all CF alleles
becoming the second most frequent severe CFTR mutation in Latvia. This mutation
should be included in ﬁrst step CF mutation screening together with dF508 mutation.
The study conﬁrms that dele2,3 mutation has severe phenotype − early presentation,
exocrine pancreas insufﬁciency and recurrent lung infections.
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“Interdepartmental and interdisciplinary working group on rare diseases” runs under
the Czech Ministry of Health, and coordinates the establishment of centres for rare
diseases.
A team of experts from CF Centre in University Hospital Brno currently cares for
64 children and 34 adults with Cystic Fibrosis (CF). University Hospital Brno is also
responsible for newborn screening for CF(NSCF) for the Moravia region.
From December 2009 till the end of December 2013, 161 917 newborns were examined
under the NSCF at the University Hospital Brno. DNA analysis of the CFTR gene was
carried out in 1846 newborns, representing 1.14%. One or two mutations in CFTR
gene were found in 10% of newborns. We detected 20 different mutations in the CFTR
gene, the most frequent were the mutations F508del (113), CFTRdele2,3 (21 kb) (18)
and D1152H (14).
The DNA analysis of the CFTR gene we also perform within the genetic prevention
for 400–500 people per year, which represent about 20% of patients examined in our
laboratory of DNA diagnostics. In this group, we detected the pathological CF allele
in more than 15% individuals.
Centres for Orphan cooperate with patient organisations associated in the Czech
Association of Rare Diseases. An important part of the work of all experts on rare
diseases is an effort to raise awareness about rare diseases among specialists and the
public. Lecture devoted to Cystic Fibrosis in November 2013 was a part of the activities
within the European day for CF. Teaching of Clinical Genetics at Masaryk University
Brno and public lectures dedicated on rare diseases in the Mendel Museum Masaryk
University (www.mendelmuseum.muni.cz) illustrate activities our CF Center.
